Client Services : 949-340-7598
General & Sales : 949-472-8000
Study Management : 949-472-8080

Publications

Mosaic Laboratories has co-authored or been referenced in the following publications with pharmaceutical and biotechnology companies:

2020
Pfizer and Mosaic Laboratories (Referenced in Methods)

Murphy DA, Rini BI, Escudier B, Motzer RJ, Wang P, Li S, Williams JA, et al.

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncol. 2020 May 4. doi: 10.2217/fon-2020-0212

ARTICLE
2020
Cofactor Genomics and Mosaic Laboratories (Referenced in Methods)

Schillebeeckx I, Armstrong JR, Forys JT, Hiken J, Earls J, Flanagan KC, et al.

Analytical Performance of an Immunoprofiling Assay Based on RNA Models. J Mol Diagn. 2020 Apr;22(4):555-570.

ARTICLE
2020
Pfizer and Mosaic Laboratories (Referenced in Methods)

Gopal AK, Levy R, Houot R, Patel SP, Popplewell L, Jacobson C, et al.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Mar 6. doi: 10.1158/1078-0432.CCR-19-2973.

ARTICLE
2019
Pfizer and Mosaic Laboratories (Referenced in Methods)

Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, et al.

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer. 2019 Dec 4;7(1):342.

ARTICLE
2019
Celldex and Mosaic Laboratories (Referenced in Methods)

Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, et al.

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children’s Oncology Group. Eur J Cancer. 2019 Nov;121:177-183.

ARTICLE
2019
BMS and Mosaic Laboratories (Referenced in Methods)

Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, et al.

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Nov 15;25(22):6709-6720.

ARTICLE
2019
Immune Design and Mosaic Laboratories (Referenced in Methods)

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, et al.

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1. Front Med (Lausanne). Clin Cancer Res. 2019 Jun 21

ARTICLE
2019
Amgen and Mosaic Laboratories (Referenced in Methods)

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2018 Aug 9;174(4):1031-1032.

ARTICLE
2019
Merck KGaA and Mosaic Laboratories (Referenced in Methods)

Ihling C, Naughton 2, Zhang Y, Rolfe PA, Frick-Krieger E, Terracciano LM, Dussault I

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Front Med (Lausanne). 2019 Feb 8;6:15

ARTICLE
2019
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, et al.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. Br J Cancer. 2019 May;120(10):975-981.

ARTICLE
2019
Kite Pharmaceuticals and Mosaic Laboratories (Referenced in Methods)

Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, et al.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma. Cancer Immunol Immunother. 2019 May;68(5):743-751

ARTICLE
2019
St. Marianna University School of Medicine and Mosaic Laboratories (Referenced in Methods)

Nakajima TE, Boku N, Doi A, Arai H, Mizukami T, Horie Y, et al.

Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. Invest New Drugs. 2019 Apr 24

ARTICLE
2019
Celldex Therapeutics and Mosaic Laboratories (Referenced in Methods)

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, et al.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 Apr 1;125(7):1113-1123.

ARTICLE
2019
Immune Design and Mosaic Laboratories (Referenced in Methods)

Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, et al.

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1. Cancer Immunol Immunother (2019). https://doi.org/10.1007/s00262-019-02331-x.

ARTICLE
2018
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Aghajanian C, Bell-McGuinn KM, Burris HA 3rd, Siu L8, Stayner LA, Wheler JJ, et al.

A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs. 2018 Dec;36(6).

ARTICLE
2018
Amgen and Mosaic Laboratories (Referenced in Methods)

Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, et al.

A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018 Dec;36(6):1060-1071.

ARTICLE
2018
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480-1492.

ARTICLE
2018
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, et al.

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018 Aug 29;9(1):3503.

ARTICLE
2018
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al.

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018 May 14; 33(5): 843–852.

ARTICLE
2018
AbbVie and Mosaic Laboratories (Referenced in Methods)

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, et al.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 Apr;118(8):1042-1050.

ARTICLE
2018
Pfizer and Mosaic Laboratories (Referenced in Methods)

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, et al.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clin Cancer Res. 2018 Apr 1;24(7):1554-1561.

ARTICLE
2018
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Krähenbühl L, Goldinger SM, Mangana J, Kerl K, Chevolet I, Brochez L, et al.

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. Neoplasia. 2018 Feb;20(2):218-225.

ARTICLE
2017
Amgen and Mosaic Laboratories (Referenced in Methods)

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 7;170(6):1109-1119.

ARTICLE
2017
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502.

ARTICLE
2017
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312-322.

ARTICLE
2017
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Yu H, Batenchuk C, Badzio A, Boyle TA, Czapiewski P, Chan DC, Lu X, et al.

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Thorac Oncol. 2017 Jan;12(1):110-120.

ARTICLE
2016
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):943-55.

ARTICLE
2016
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Mukai H, Saeki T, Aogi K, Naito Y, Matsubara N, Shigekawa T, et al.

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. Cancer Sci. 2016 Oct; 107(10): 1465–1470.

ARTICLE
2016
Bristol-Myers Squibb and Mosaic Laboratories (Referenced in Methods)

Choueiri TK, Fishman MN, Escudier B, McDermott DF, Drake CG, Kluger H, et al.

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Can Res. 2016 Nov 15;22(22):5461-5471

ARTICLE
2016
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, et al.

Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Mol Imaging Biol. 2016 Jun;18(3):446-53.

ARTICLE
2015
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, et al.

Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies. J Nucl Med. 2015 Dec;56(12):1828-35.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Ciprotti M, Tebbutt NC, Lee FT, Lee ST, Gan HK, McKee DC, et al.

Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2015 Aug 20;33(24):2609-16.

ARTICLE
2015
AbbVie and Mosaic Laboratories (Referenced in Methods)

Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, et al.

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015 Oct;26(10):2173-9.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Nishio M, Horiike A, Murakami H, Yamamoto N, Kaneda H, Nakagawa K, et al.

Phase I Study of the HER3-targeted Antibody Patritumab (U3-1287) Combined with Erlotinib in Japanese Patients with Non-small Cell Lung Cancer. Lung Cancer. 2015 Jun;88(3):275-81.

ARTICLE
2015
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Mendell J, Freeman DJ, Feng W, Hettmann T, Schneider M, Blum S, et al.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine, 2015 Mar; 2(3): 264-271.

ARTICLE
2015
Bayer and Mosaic Laboratories (Referenced in Methods)

Wong ALA, Lim JSJ, Sinha A, Gopinathan A, Lim R, Tan C-S, et al.

Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. Journal of Translational Medicine, 2015 Feb; 13: 57.

ARTICLE
2014
Celldex Therapeutics and Mosaic Laboratories (Referenced in Methods)

Patrick A. Ott, Omid Hamid, Anna C. Pavlick, Harriet Kluger, Kevin B. Kim, Peter D. Boasberg, et al.

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Journal of Clinical Oncology,2014 Nov; 32(32):3659-3666.

ARTICLE
2014
Daiichi Sankyo and Mosaic Laboratories (Referenced in Methods)

Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, et al.

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6.

ARTICLE
2014
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, et al.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2014 Sep 1;20(17):4449-58.

ARTICLE
2014
Millennium Pharmaceuticals and Mosaic Laboratories (Referenced in Methods)

Friedberg JW1, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, et al.

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 2014 Jan 1;32(1):44-50.

ARTICLE
2014
Celldex and Mosaic Laboratories (Referenced in Methods)

Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, et al.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014 Nov 10;32(32):3659-66.

ARTICLE
2014
Merck and Mosaic Laboratories

Sun A, Lam RL, Harman A, Pavlick AC, Herman GA, Dauffenbach LM, Kerfoot CA. Huang P, Demuth T and Iannone R.

Induction of CDC2 Phosphorylation in Skin Biopsies from Patients with Solid Tumors Undergoing DNA-Damaging Chemotherapy. Global Journal of Medical Research (K) (2014) 14(1): 11-21.

ARTICLE
2015
Memorial Sloan Kettering and Mosaic Laboratories

D’Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, et al.

Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015 Mar;46(3):357-65.

ARTICLE
2013
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al.

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE (2013) 8(7): e67583.

ARTICLE
2013
Abbott Biotherapeutics and Mosaic Laboratories (Referenced in Methods)

Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, et al.

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.

ARTICLE
2013
PharmaMar and Mosaic Laboratories

Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernández LF, Kerfoot CA, Galmarini CM.

Expression of XPG protein in human normal and tumor tissues. Int J Clin Exp Pathol. 2013; 6(2): 199–211

ARTICLE
2012
Merck and Mosaic Laboratories

Sun A, Zhou W, Lunceford J, Strack P, Dauffenbach LM, Kerfoot CA.

Level of phosphohistone H3 among various types of human cancers. BMJ Open. 2012; 2(5): e001071

ARTICLE
2012
GlaxoSmithKline and Mosaic Laboratories (Referenced in Methods)

Erickson-Miller CL, Pillarisetti K, Kirchner J, Figueroa DJ, Ottesen L, Martin AM, Liu Y, et al.

Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors. BMC Cancer. 2012 Sep 11;12:405.

ARTICLE
2012
Telormedix and Mosaic Laboratories (Referenced in Methods)

Arentsen HC, Hulsbergen-Van de Kaa CA, Jansen CFJ, Maj R, Leoni LM, Oosterwijk E, Witjes JA

Pharmacokinetics and toxicity of intravesical TMX-101: a preclinical study in pigs. BJU International. 2011 Oct;108 (7): 1210–14.

ARTICLE
2011
GlaxoSmithKline and Mosaic Laboratories (Thanked in Acknowledgements)

Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al.

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Curr Pharm Des. Br J Haematol. Clin Cancer Res. 2011 May 15;17(10):3420-30.

ARTICLE
2011
Attenuon and Mosaic Laboratories (Thanked in Acknowledgements)

Mazar AP, Ahn RW, O’Halloran TV.

Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011;17(19):1970-8.

ARTICLE
2010
EMD Serono Research Institute and Mosaic Laboratories (Referenced in Methods)

Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al.

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Curr Pharm Des. Br J Haematol. 2010 May;149(4):537-49.

ARTICLE
2010
Attenuon and Mosaic Laboratories

Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA and Mazar AP.

An anti-urokinase receptor (uPAR) antibody (ATN-658) blocks prostate cancer invasion, migration, growth and experimental skeletal metastasis in vitro and in vivo. Neoplasia. 2010 Oct;12(10):778-88

ARTICLE
2010
Proacta and Mosaic Laboratories (Referenced in Methods)

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, et al.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010 Feb 15;70(4):1573-84.

ARTICLE
2009
Vertex Pharmaceuticals and Mosaic Laboratories

Wang T, Duffy JP, Wang J, Halas S, Salituro FG, Pierce AC, Zuccola HJ, Black JR, Hogan JK, Jepson S, Shlyakter D, Mahajan S, Gu Y, Hoock T, Wood M, Furey BF, Frantz JD, Dauffenbach LM, Germann UA, Fan B, Namchuk M, Bennani YL, Ledeboer MW.

Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.

ARTICLE

Patents

Mosaic Laboratories has been referenced in the following patents and patent applications by pharmaceutical and biotechnology companies:

2012
Amgen and Mosaic Laboratories

Abraham Anderson, Kelly Oliner, Rui Tang, Elwyn Loh, Sarita Dubey

Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor (“hgf”) antibodies in esophageal and gastric cancer patients. International application number: PCT/US2012/054312

PATENT
2012
GlaxoSmithKline and Mosaic Laboratories

Auger KR, Dar MM, Fleming RA

Method of administration and treatment. Application number: US2012/044618

PATENT
2010
Telormedix and Mosaic Laboratories

Anderson A, Oliner K, Tang R, Loh E, Dubey S.

Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration. Application number: 20110319442

PATENT
2009
Proacta (Auckland Uniservices Limited) and Mosaic Laboratories

Patterson AV, Guise CP, Abbattista MR, Wilson WR, Smaill JB, Syddall S, Denny WA, Ashoorzadeh A.

Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein. Application number: PCT/NZ2009/000227

PATENT